Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2

Federica Cossu; Eloise Mastrangelo; Mario Milani; Graziella Sorrentino; Daniele Lecis; Domenico Delia; Leonardo Manzoni; Pierfausto Seneci; Carlo Scolastico; Martino Bolognesi

doi:10.1016/j.bbrc.2008.10.139

Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2

Federica Cossu, Eloise Mastrangelo, Mario Milani, Graziella Sorrentino, Daniele Lecis, Domenico Delia, Leonardo Manzoni, Pierfausto Seneci, Carlo Scolastico, Martino Bolognesi

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article

Abstract

Inhibitor of apoptosis proteins (IAPs) such as XIAP, cIAP1, and cIAP2 are upregulated in many cancer cells. Several compounds targeting IAPs and inducing cell death in cancer cells have been developed. Some of these are synthesized mimicking the N-terminal tetrapeptide sequence of Smac/DIABLO, the natural endogenous IAPs inhibitor. Starting from such conceptual design, we generated a library of 4-substituted azabicyclo[5.3.0]alkane Smac-mimetics. Here we report the crystal structure of the BIR3 domain from XIAP in complex with Smac037, a compound designed according to structural principles emerging from our previously analyzed XIAP BIR3/Smac-mimetic complexes. In parallel, we present an in silico docking analysis of three Smac-mimetics to the BIR3 domain of cIAP1, providing general considerations for the development of high affinity lead compounds targeting three members of the IAP family.

Original language	English
Pages (from-to)	162-167
Number of pages	6
Journal	Biochemical and Biophysical Research Communications
Volume	378
Issue number	2
DOIs	https://doi.org/10.1016/j.bbrc.2008.10.139
Publication status	Published - Jan 9 2009

Keywords

cIAP
Inhibition of apoptosis
Oncology
Peptidomimetics
SMAC/DIABLO
XIAP

ASJC Scopus subject areas

Biochemistry
Biophysics
Cell Biology
Molecular Biology

Access to Document

10.1016/j.bbrc.2008.10.139

Fingerprint Dive into the research topics of 'Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2'. Together they form a unique fingerprint.

Cite this

Cossu, F., Mastrangelo, E., Milani, M., Sorrentino, G., Lecis, D., Delia, D., Manzoni, L., Seneci, P., Scolastico, C., & Bolognesi, M. (2009). Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2. Biochemical and Biophysical Research Communications, 378(2), 162-167. https://doi.org/10.1016/j.bbrc.2008.10.139

Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2. / Cossu, Federica; Mastrangelo, Eloise; Milani, Mario; Sorrentino, Graziella; Lecis, Daniele; Delia, Domenico; Manzoni, Leonardo; Seneci, Pierfausto; Scolastico, Carlo; Bolognesi, Martino.

In: Biochemical and Biophysical Research Communications, Vol. 378, No. 2, 09.01.2009, p. 162-167.

Research output: Contribution to journal › Article

@article{be08c4e28c774195ae0b07f9ee3c0610,

title = "Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2",

abstract = "Inhibitor of apoptosis proteins (IAPs) such as XIAP, cIAP1, and cIAP2 are upregulated in many cancer cells. Several compounds targeting IAPs and inducing cell death in cancer cells have been developed. Some of these are synthesized mimicking the N-terminal tetrapeptide sequence of Smac/DIABLO, the natural endogenous IAPs inhibitor. Starting from such conceptual design, we generated a library of 4-substituted azabicyclo[5.3.0]alkane Smac-mimetics. Here we report the crystal structure of the BIR3 domain from XIAP in complex with Smac037, a compound designed according to structural principles emerging from our previously analyzed XIAP BIR3/Smac-mimetic complexes. In parallel, we present an in silico docking analysis of three Smac-mimetics to the BIR3 domain of cIAP1, providing general considerations for the development of high affinity lead compounds targeting three members of the IAP family.",

keywords = "cIAP, Inhibition of apoptosis, Oncology, Peptidomimetics, SMAC/DIABLO, XIAP",

author = "Federica Cossu and Eloise Mastrangelo and Mario Milani and Graziella Sorrentino and Daniele Lecis and Domenico Delia and Leonardo Manzoni and Pierfausto Seneci and Carlo Scolastico and Martino Bolognesi",

year = "2009",

month = jan,

day = "9",

doi = "10.1016/j.bbrc.2008.10.139",

language = "English",

volume = "378",

pages = "162--167",

journal = "Biochemical and Biophysical Research Communications",

issn = "0006-291X",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2

AU - Cossu, Federica

AU - Mastrangelo, Eloise

AU - Milani, Mario

AU - Sorrentino, Graziella

AU - Lecis, Daniele

AU - Delia, Domenico

AU - Manzoni, Leonardo

AU - Seneci, Pierfausto

AU - Scolastico, Carlo

AU - Bolognesi, Martino

PY - 2009/1/9

Y1 - 2009/1/9

N2 - Inhibitor of apoptosis proteins (IAPs) such as XIAP, cIAP1, and cIAP2 are upregulated in many cancer cells. Several compounds targeting IAPs and inducing cell death in cancer cells have been developed. Some of these are synthesized mimicking the N-terminal tetrapeptide sequence of Smac/DIABLO, the natural endogenous IAPs inhibitor. Starting from such conceptual design, we generated a library of 4-substituted azabicyclo[5.3.0]alkane Smac-mimetics. Here we report the crystal structure of the BIR3 domain from XIAP in complex with Smac037, a compound designed according to structural principles emerging from our previously analyzed XIAP BIR3/Smac-mimetic complexes. In parallel, we present an in silico docking analysis of three Smac-mimetics to the BIR3 domain of cIAP1, providing general considerations for the development of high affinity lead compounds targeting three members of the IAP family.

AB - Inhibitor of apoptosis proteins (IAPs) such as XIAP, cIAP1, and cIAP2 are upregulated in many cancer cells. Several compounds targeting IAPs and inducing cell death in cancer cells have been developed. Some of these are synthesized mimicking the N-terminal tetrapeptide sequence of Smac/DIABLO, the natural endogenous IAPs inhibitor. Starting from such conceptual design, we generated a library of 4-substituted azabicyclo[5.3.0]alkane Smac-mimetics. Here we report the crystal structure of the BIR3 domain from XIAP in complex with Smac037, a compound designed according to structural principles emerging from our previously analyzed XIAP BIR3/Smac-mimetic complexes. In parallel, we present an in silico docking analysis of three Smac-mimetics to the BIR3 domain of cIAP1, providing general considerations for the development of high affinity lead compounds targeting three members of the IAP family.

KW - cIAP

KW - Inhibition of apoptosis

KW - Oncology

KW - Peptidomimetics

KW - SMAC/DIABLO

KW - XIAP

UR - http://www.scopus.com/inward/record.url?scp=57049144228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049144228&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2008.10.139

DO - 10.1016/j.bbrc.2008.10.139

M3 - Article

C2 - 18992220

AN - SCOPUS:57049144228

VL - 378

SP - 162

EP - 167

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -